Germline and somatic mutations in BRCA1 have been identified in approximately one‐third of ovarian carcinomas, and their presence is highly predictive of primary platinum and PARP (Poly‐ADP‐Ribose‐Polymerase) inhibitors sensitivity and favorable progression‐free and overall survival [1, 2, 3, 4]. Here, BRCA1 is linked to ovarian carcinoma.